دورية أكاديمية
Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.
| العنوان: | Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities. |
|---|---|
| المؤلفون: | Imperiale A; Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg University Hospitals, Strasbourg, France. a.imperiale@icans.eu.; Molecular Imaging, DRHIM, Institut Pluridisciplinaire Hubert Curien (IPHC), UMR7178, CNRS, University of Strasbourg, Strasbourg, France. a.imperiale@icans.eu., Berti V; Nuclear Medicine, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy., Burgy M; Medical Oncology, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg, France.; Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, Illkirch, 67401, France., Cazzato RL; Interventional Radiology, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France., Piccardo A; Nuclear Medicine, Ente Ospedaliero Ospedali Galliera, Genoa, Italy., Treglia G; Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. |
| المصدر: | Reviews in endocrine & metabolic disorders [Rev Endocr Metab Disord] 2024 Feb; Vol. 25 (1), pp. 187-202. Date of Electronic Publication: 2023 Sep 16. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Germany NLM ID: 100940588 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2606 (Electronic) Linking ISSN: 13899155 NLM ISO Abbreviation: Rev Endocr Metab Disord Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005-: Heidelberg : Springer Original Publication: Boston : Kluwer Academic Publishers, c2000- |
| مواضيع طبية MeSH: | Carcinoma, Medullary*/pathology , Thyroid Neoplasms*/pathology , Carcinoma, Neuroendocrine*, Humans ; Positron-Emission Tomography/methods ; Positron Emission Tomography Computed Tomography ; Tomography, X-Ray Computed/methods |
| مستخلص: | Due to its rarity and non-specific clinical presentation, accurate diagnosis, and optimal therapeutic strategy of medullary thyroid carcinoma (MTC) remain challenging. Molecular imaging provides valuable tools for early disease detection, monitoring treatment response, and guiding personalized therapies. By enabling the visualization of molecular and cellular processes, these techniques contribute to a deeper understanding of disease mechanisms and the development of more effective clinical interventions. Different nuclear imaging techniques have been studied for assessing MTC, and among them, PET/CT utilizing multiple radiotracers has emerged as the most effective imaging method in clinical practice. This review aims to provide a comprehensive summary of the current use of advanced molecular imaging modalities, with a particular focus on PET/CT, for the management of patients with MTC. It aims to guide physicians towards a rationale for the use of molecular imaging also including theranostic approaches and novel therapeutical opportunities. Overall, we emphasize the evolving role of nuclear medicine in MTC. The integration of diagnostics and therapeutics by in vivo molecular imaging represents a major opportunity to personalize treatment for individual patients, with targeted radionuclide therapy being one representative example. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19:152–61. (PMID: 1362074010.1210/jcem-19-1-152) Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–5. (PMID: 1711900010.1210/jc.2006-1590) Essig GF Jr, Porter K, Schneider D, Arpaia D, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas LH, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Thyroid. 2016;26:1563–72. (PMID: 27604949645348710.1089/thy.2016.0255) Trimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine. 2023;6 (ahead of print). Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, Haas OA, Niederle B. Endocr Relat Cancer. 2009;16:243–53. (PMID: 1898717010.1677/ERC-08-0059) Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab. 2012;97:1547–53. (PMID: 2239950810.1210/jc.2011-2534) Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1995;42:581–8. (PMID: 10.1016/0092-8674(85)90115-1) Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML. Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol. 2008;22:149–63. (PMID: 1832898710.1016/j.berh.2007.11.010) Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9. (PMID: 891885510.1001/jama.1996.03540190047028) Moley JF. (2010) Medullary thyroid carcinoma: Management of lymph node metastases. J Natl Compr Canc Netw. 2010;8:549–556. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised american thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610. (PMID: 25810047449062710.1089/thy.2014.0335) Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, Tziomalos K, Doumala E, Patakiouta F. Predictive factors that influence the course of medullary thyroid carcinoma. Int J Clin Oncol. 2014;19:445–51. (PMID: 2383228610.1007/s10147-013-0588-8) Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK. Medullary thyroid Cancer: clinico-pathological Profile and Outcome in a Tertiary Care Center in North India. World J Surg. 2011;35:1273–80. (PMID: 2147968410.1007/s00268-011-1086-7) Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4:64–71. (PMID: 2660806610.1016/S2213-8587(15)00337-X) Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46. (PMID: 24002501416481310.1200/JCO.2012.48.4659) Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–41. (PMID: 2202514610.1200/JCO.2011.35.5040) Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28:2813–9. (PMID: 29045520583404010.1093/annonc/mdx479) Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, et al. Genetic Landscape of somatic mutations in a large cohort of sporadic medullary thyroid Carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324–36. (PMID: 31605946681765610.1016/j.isci.2019.09.030) Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491–501. (PMID: 3411819810.1016/S2213-8587(21)00120-0) 10, Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered thyroid cancers. N Engl J Med. 2020;383:825–35. (PMID: 10.1056/NEJMoa2005651) Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a calcitonine (GETC). Br J Cancer. 1995;71:363–5. (PMID: 7530987203356910.1038/bjc.1995.73) Wang L, Kou H, Chen W, Lu M, Zhou L, Zou C. The diagnostic value of Ultrasound in Medullary thyroid carcinoma: a comparison with computed tomography. Technol Cancer Res Treat. 2020;19:153303382090583. (PMID: 10.1177/1533033820905832) Liu MJ, Liu ZF, Hou YY, Men YM, Zhang YX, Gao LY, Liu H. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Oncotarget. 2017;8:27520–8. (PMID: 28460476543235410.18632/oncotarget.15897) Lai X, Liu M, Xia Y, Wang L, Bi Y, Li X, Zhang B, Yang M, Dai Q, Jiang Y. Hypervascularity is more frequent in medullary thyroid carcinoma: compared with papillary thyroid carcinoma. Medicine. 2016;95:e5502. (PMID: 27930537526600910.1097/MD.0000000000005502) Valderrabano P, Klippenstein DL, Tourtelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, McIver B. New american thyroid Association Sonographic patterns for thyroid nodules perform well in medullary thyroid carcinoma: institutional experience, systematic review, and Meta-Analysis. Thyroid. 2016;26:1093–100. (PMID: 27267210787199010.1089/thy.2016.0196) Ferrarazzo G, Camponovo C, Deandrea M, Piccardo A, Scappaticcio L, Trimboli P. Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis. Clin Endocrinol (Oxf). 2022;97:532–40. (PMID: 3541985510.1111/cen.14739) Trimboli P, Castellana M, Piccardo A, Romanelli F, Grani G, Giovanella L, Durante C. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. Rev Endocr Metab Disord. 2021;22:453–60. (PMID: 3295917410.1007/s11154-020-09592-3) Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid Cancer. J Clin Endocrinol Metab. 2010;95:2655–63. (PMID: 2033902610.1210/jc.2009-2368) Klain M, Hadoux J, Nappi C, Finessi M, Ambrosio R, Schlumberger M, Cuocolo A, Deandreis D, Salvatore D. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocrine. 2022;75:330–7. (PMID: 3474816810.1007/s12020-021-02930-8) Debnam JM, Guha-Thakurta N, Sun J, Wei W, Zafereo ME, Cabanillas ME, Buisson NM, Schellingerhout D. Distinguishing recurrent thyroid Cancer from residual nonmalignant thyroid tissue using multiphasic multidetector CT. AJNR Am J Neuroradiol. 2020;41:844–51. (PMID: 32327435722818610.3174/ajnr.A6519) Fitzgerald RT, Kuruva M, David R, Samant RS, Kumar M, Van Hemert R, Angtuaco EJ, Bodenner D, Stack BC Jr. Characterization of thyroid nodules by 4-Dimensional Computed Tomography: initial experience. J Comput Assist Tomogr. 2017;41:195–8. (PMID: 2756002510.1097/RCT.0000000000000495) Gürsoy Çoruh A, Uzun Ç, Kul M, Akkaya Z, Halil Elhan A, Gökcan K. The impact of arterial phase on the detection of cervical lymph node metastasis from papillary thyroid carcinoma: a quantitative evaluation on multiphasic computed tomography. J Comput Assist Tomogr. 2020;44:262–8. (PMID: 3219580610.1097/RCT.0000000000001005) Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105–13. (PMID: 1616288110.1056/NEJMoa043999) Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61–77. (PMID: 3148242910.1007/s00259-019-04458-6) Castinetti F, Taïeb D. Positron emission tomography imaging in medullary thyroid carcinoma: time for reappraisal? Thyroid. 2021;31:151–5. (PMID: 3319186610.1089/thy.2020.0674) Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B, Kroiss AS. PET with different radiopharmaceuticals in neuroendocrine neoplasms: an umbrella review of published meta-analyses. Cancers. 2021;13:5172. (PMID: 34680321853394310.3390/cancers13205172) Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, Montravers F. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775–9. (PMID: 2254687710.1097/MNM.0b013e3283543304) Fargette C, Imperiale A, Taïeb D. Molecular imaging of endocrine neoplasms with emphasis on 18F-DOPA PET: a practical approach for well-tailored imaging protocols. Q J Nucl Med Mol Imaging. 2022;66:141–7. (PMID: 3534367010.23736/S1824-4785.22.03450-1) Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, Mazal P, Hacker M, Hartenbach M. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. 2018;45:2159–69. (PMID: 29766245618240110.1007/s00259-018-4045-9) Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A. Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1856–83. (PMID: 3154999810.1093/annonc/mdz400) Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfurst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425–34. (PMID: 1915642310.1007/s00330-008-1280-7) Brammen L, Niederle MB, Riss P, Scheuba C, Selberherr A, Karanikas G, Bodner G, Koperek O, Niederle B. Medullary thyroid carcinoma: do Ultrasonography and F-DOPA-PET-CT influence the initial Surgical Strategy? Ann Surg Oncol. 2018;25:3919–27. (PMID: 30306375624503110.1245/s10434-018-6829-3) Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71. (PMID: 1120245410.1007/s002590000404) Treglia G, Rufini V, Piccardo A, Imperiale A. Update on management of medullary thyroid carcinoma: focus on Nuclear Medicine. Semin Nucl Med. 2023 (Ahead of print). Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604–9. (PMID: 1743599610.1007/s00259-007-0425-2) Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33. (PMID: 2045043210.1089/thy.2009.0342) Treglia G, Cocciolillo F, Di Nardo F, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290–9. (PMID: 2281907610.1016/j.acra.2012.05.008) Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, Schneegans O, Mundler O, Abdullah AE, Sebag F, Imperiale A, Taieb D. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:1027–33. (PMID: 2649769910.1007/s00259-015-3227-y) Rotania M, Chabrier G, Imperiale A. Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient. Endocrine. 2019;66:691–2. (PMID: 3147816010.1007/s12020-019-02074-w) Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S. F-18-Dopa positron emission tomography/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent/recurrent disease of medullary thyroid cancer patients. Thyroid. 2019;29:1457–64. (PMID: 3153023510.1089/thy.2018.0351) Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45. (PMID: 2252788910.1007/s12020-012-9671-6) Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 1-F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136–42. (PMID: 2249818410.1111/j.1754-9485.2012.02344.x) Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, Scalorbi F, Donner D, Alongi P, Young AIMN, Working Group. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med. 2018;32:7–15. (PMID: 2898676410.1007/s12149-017-1213-0) Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. ., and american thyroid Association Guidelines Task Force on Medullary thyroid carcinoma. Medullary thyroid cancer: management guidelines of the american thyroid Association. Thyroid. 2009;19:565–612. (PMID: 1946969010.1089/thy.2008.0403) Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, Exarhos D, Alevizaki M. Correlation between calcitonin levels and [(18)F]FDG-PET/CT in the detection of recurrence in patients with sporadic and Hereditary Medullary thyroid Cancer. ISRN Endocrinol. 2012;2012:375231. (PMID: 22655204335796110.5402/2012/375231) Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90. (PMID: 1772607110.1210/jc.2007-1211) Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine. 2020;67:9–19. (PMID: 3173477910.1007/s12020-019-02131-4) Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, Fanti S, Gross MD, Al-Nahhas A, Rubello D. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21. (PMID: 2010064710.1016/j.ejso.2010.01.001) Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F. 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1501–10. (PMID: 2480611010.1007/s00259-014-2772-0) Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med. 2018;59:756–61. (PMID: 2902598310.2967/jnumed.117.199778) Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, Lapa C. Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine. 2019;63:293–300. (PMID: 3020677210.1007/s12020-018-1749-3) Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J, Todica A, Gildehaus FJ, Kunz WG, Stahl R, Spitzweg C, Ricke J, Kazmierczak PM. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging. 2019;14:19:73. (PMID: 10.1186/s40644-019-0263-z) Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, Ambrosini V, Cremonini N, Santimaria M, Versari A, Fanti S, Giordano A, Rufini V. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80. (PMID: 2222316910.1007/s00259-011-2031-6) Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, Wagner J, Funari MBG. (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017;44:1695–701. (PMID: 2842904410.1007/s00259-017-3701-9) Lee SW, Shim SR, Jeong SY, Kim SJ. Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a Network Meta-analysis. Clin Nucl Med. 2020;45:341–8. (PMID: 3204972310.1097/RLU.0000000000002940) Pajak C, Cadili L, Nabata K, Wiseman SM. 68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: a systematic review. Am J Surg. 2022;224:670–5. (PMID: 3538293310.1016/j.amjsurg.2022.03.046) Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens Greece). 2017;16:262–72. Reubi JC, Waser B, Maecke HR, Rivier JE. Highly increased 125i-Jr11 antagonist binding in vitro reveals novel indications for Sst2 targeting in human cancers. J Nucl Med. 2016;58:300–6. (PMID: 2756187810.2967/jnumed.116.177733) Imperiale A, Jha A, Meuter L, Nicolas GP, Taïeb D, Pacak K. The emergence of somatostatin antagonist-based theranostics: paving the Road toward another success? J Nucl Med. 2023;64:682–4. (PMID: 367591981015212810.2967/jnumed.123.265406) Ueda CE, Duarte PS, de Castroneves LA, Coura-Filho GB, Sado HN, Sapienza MT, Hoff AO, Buchpiguel CA. Comparison of 18F-NaF PET/CT with other imaging methods in the detection of bone metastases in patients with medullary thyroid cancer: a report of a series of 31 cases. Nucl Med Mol Imaging. 2020;54:281–91. (PMID: 33281999770498810.1007/s13139-020-00666-3) Ueda CE, Duarte PS, de Castroneves LA, Flávio J, Marin G, Sado HN, Sapienza MT, Hoff AO, Buchpiguel CA. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Nucl Med Commun. 2020;41:469–760. (PMID: 3218716010.1097/MNM.0000000000001175) Li C, Zhang P, Nie R, Gong X, Xie J, Yu Z, Wang C, Zhang H, Yan R, Lu Z. Targeting amyloids with [18F]AV-45 for medullary thyroid carcinoma positron emission tomography/computed tomography imaging: a pilot clinical study. Mol Pharm. 2022;19:584–91. (PMID: 34982563882675710.1021/acs.molpharmaceut.1c00680) Jamsek J, Hocevar M, Bergant D, Zaletel K, Rep S, Lezaic L. Diagnostic value of [18F]Fluorocholine PET/CT in detection of primary medullary thyroid cancer. Ann Nucl Med. 2021;35:429–37. (PMID: 3354432010.1007/s12149-021-01579-7) Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, Kim SW, Chung JH. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J. 2010;57:1045–54. (PMID: 2097836510.1507/endocrj.K10E-258) Uprimny C, von Guggenberg E, Svirydenka A, Mikołajczak R, Hubalewska-Dydejczyk A, Virgolini IJ. Comparison of PET/CT imaging with FDOPA and cholecystokinin-2 receptor targeting 68Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:935–6. (PMID: 3274804810.1007/s00259-020-04963-z) Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177Lu-DOTA-PP-F11N:does the use of protease inhibitors further improve in vivo distribution? J Nucl Med. 2019;60:393–9. (PMID: 3000210710.2967/jnumed.118.207845) von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G, Virgolini IJ. Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer. J Nucl Med. 2023 (Ahead of print). Wong JYC, Yamauchi DM, Adhikarla V, Simpson J, Frankel PH, Fong Y, Melstrom KA, Chen YJ, Salehian BD, Woo Y, Dandapani SV, Colcher DM, Poku EK, Yazaki PJ, Wu AM, Shively JE. First-In-human pilot PET immunoimaging study of 64Cu-anti-carcinoembryonic antigen monoclonal antibody (hT84.66-M5A) in patients with carcinoembryonic antigen-producing cancers. Cancer Biother Radiopharm. 2023;38:26–37. (PMID: 36154291) Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Anti-CEA pretargeted immuno-PET shows higher sensitivity than DOPA PET/CT in detecting relapsing metastatic medullary thyroid carcinoma: Post hoc analysis of the iPET-MTC study. J Nucl Med. 2021;62:1221–7. (PMID: 33547213888289410.2967/jnumed.120.252791) Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Clinical results in medullary thyroid carcinoma suggest high potential of pretargeted immuno-PET for tumor imaging and theranostic approaches. Front Med. 2019;6:124. (PMID: 10.3389/fmed.2019.00124) Ballal S, Yadav MP, Moon ES, Rösch F, ArunRaj ST, Agarwal S, Tripathi M, Sahoo RK, Bal C. First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer. Clin Nucl Med. 2022;47:e444–5. (PMID: 3550743510.1097/RLU.0000000000004164) Kuyumcu S, Isık EG, Sanli Y. Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT. Endocrine. 2021;74:727–8. (PMID: 3416946210.1007/s12020-021-02800-3) Ballal S, Yadav MP, Roesch F, Raju S, Satapathy S, Sheokand P, Moon ES, Martin M, Agarwal S, Tripathi M, Bal C. Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC PET/CT imaging for the follow-up surveillance of patients with medullary thyroid cancer. Thyroid. 2023;12 (Ahead of print). Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, Bal C. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET/CT: exploring new theranostic avenues. Clin Nucl Med. 2018;43:359–60. (PMID: 2948544910.1097/RLU.0000000000002010) Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:925–51. (PMID: 3594802910.6004/jnccn.2022.0040) Hofland J, Brabander T, Verburg FA, Feelders RA, de Herder WW. Peptide receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2022;107:3199–208. (PMID: 36198028969383510.1210/clinem/dgac574) Czajkowski M, Kaemmerer D, Sänger J, Sauter G, Wirtz RM, Schulz S, Lupp A. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies. BMC Cancer. 2022;7:22:740. (PMID: 10.1186/s12885-022-09839-z) Hayes AR, Crawford A, Al Riyami K, Tang C, Bomanji J, Baldeweg SE, Wild D, Morganstein D, Harry A, Grozinsky-Glasberg S, Oleinikov K, Khoo B, Caplin ME, Nicolas GP, Grossman AB. Metastatic medullary thyroid Cancer: the role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and peptide receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2021;106:e4903–16. (PMID: 34379772) Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;20:21:579. (PMID: 10.1186/s12885-021-08257-x) Liu Q, Kulkarni HR, Zhao T, Schuchardt C, Chen X, Zhu Z, Zhang J, Baum RP. Peptide receptor Radionuclide Therapy in patients with Advanced Progressive Medullary thyroid Cancer: efficacy, Safety, and survival predictors. Clin Nucl Med. 2023;48:221–7. (PMID: 3672388110.1097/RLU.0000000000004539) von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on Preclinical Development and clinical translation of Cholecystokinin-2 receptor targeting Radiopharmaceuticals. Cancers (Basel). 2021;18:13:5776. (PMID: 10.3390/cancers13225776) Hasenauer N, Higuchi T, Deschler-Baier B, Hartrampf PE, Pomper MG, Rowe SP, Fassnacht M, Buck AK, Werner RA. Visualization of Tumor Heterogeneity in Advanced Medullary thyroid carcinoma by Dual-Tracer Molecular Imaging: revealing the Theranostic potential of SSTR- and PSMA-Directed Endoradiotherapy. Clin Nucl Med. 2022;47:651–2. (PMID: 3508517210.1097/RLU.0000000000004082) Martin M, Ballal S, Yadav MP, Bal C, Van Rymenant Y, De Loose J, Verhulst E, De Meester I, Van Der Veken P, Roesch F. Novel generation of FAP inhibitor-based homodimers for Improved Application in Radiotheranostics. Cancers (Basel). 2023;21;15:1889. Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36:514–24. (PMID: 3415431010.3803/EnM.2021.1082) |
| فهرسة مساهمة: | Keywords: 18F-DOPA; 18F-FDG; 68Ga-DOTA peptides; Medullary thyroid carcinoma; Molecular imaging; Nuclear medicine; PET; Theranostics |
| SCR Disease Name: | Thyroid cancer, medullary |
| تواريخ الأحداث: | Date Created: 20230915 Date Completed: 20240125 Latest Revision: 20240125 |
| رمز التحديث: | 20240125 |
| DOI: | 10.1007/s11154-023-09836-y |
| PMID: | 37715050 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!